Morepen Laboratories Ltd

Morepen Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 24 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 29 January 2026, providing investors with the latest insights into its performance and outlook.

Morepen Laboratories Ltd has touched a new 52-week low of Rs.33.48 today, marking a significant decline in its stock price amid continued underperformance relative to its sector and benchmark indices.

Morepen Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, recorded a new 52-week low of Rs.34.1 today, marking a significant decline in its stock price amid broader market pressures and company-specific performance factors.

Morepen Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.34.38 today, marking a significant decline amid a broader market downturn and company-specific performance issues.

Morepen Laboratories Ltd touched a fresh 52-week low of Rs.36.27 today, marking a significant decline in its stock price amid sustained downward momentum. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on the company’s financial performance and market sentiment.

Morepen Laboratories Ltd has reached a new 52-week low of Rs.37.18 today, marking a significant decline amid a broader market downturn. The stock has underperformed its sector and the benchmark indices, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology industry.

Morepen Laboratories Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.37.82 today, marking a significant decline amid a sustained downward trend over recent sessions.

Morepen Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 24 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 07 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Morepen Laboratories Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 24 Nov 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 27 December 2025, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Morepen Laboratories has reached a new 52-week low of Rs.39.32 today, marking a significant decline amid a sustained downward trend. The stock has been trading below all major moving averages and has recorded losses over the past four consecutive sessions, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Morepen Laboratories has reached a new 52-week low of Rs.40, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on the company’s financial performance and market valuation.

Morepen Labs., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and technical outlook. The recent assessment highlights subdued financial performance and technical indicators that have influenced the stock’s current market perception.

Morepen Laboratories has reached a new 52-week low of Rs.40.01, marking a significant decline amid a sustained downward trajectory. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on the company’s financial performance and market sentiment.

Shares of Morepen Laboratories touched a fresh 52-week low of Rs.41.33 today, marking a significant decline amid broader market fluctuations and sectoral pressures. The stock has been underperforming the Pharmaceuticals & Biotechnology sector and continues to trade below all major moving averages.

Morepen Laboratories has reached a new 52-week low of Rs.41.33, marking a significant decline amid ongoing downward momentum. The stock has underperformed its sector and broader market indices, reflecting persistent challenges in its financial performance over the past year.

Morepen Laboratories, a player in the Pharmaceuticals & Biotechnology sector, is currently navigating a complex market environment marked by subdued financial results and cautious technical indicators. Recent shifts in evaluation metrics reflect a nuanced perspective on the company’s quality, valuation, financial trends, and technical outlook, underscoring the challenges it faces amid broader market dynamics.